What question did this study set out to answer?

To compare real-world outcomes of triptans and gepants for acute migraine therapy and identify predictors of treatment response.

Comparative analysis of real‐world acute prescription migraine therapy outcomes: Insights from the HeAD – US study

View Full Paper

Ask AI

Bookmark

Authors

Cross-sectional data show gepants improve pain relief in chronic migraine patients, suggesting better therapy options.

To compare real-world outcomes of triptans and gepants for acute migraine therapy and identify predictors of treatment response.
Cross-sectional analysis of migraine sufferers using the Migraine Buddy application
Examined 2-h pain freedom and 24-h pain relief outcomes
Identified demographic, clinical, and treatment-related predictors
Gepant users had 36% higher odds of achieving 24hPR compared to triptan users
No significant differences were observed in 2hPF outcomes between the two groups
Higher severity and frequency of migraines negatively impacted treatment effectiveness

Teichrow et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Cross-sectional data show gepants improve pain relief in chronic migraine patients, suggesting better therapy options.

To compare real-world outcomes of triptans and gepants for acute migraine therapy and identify predictors of treatment response.
Cross-sectional analysis of migraine sufferers using the Migraine Buddy application
Examined 2-h pain freedom and 24-h pain relief outcomes
Identified demographic, clinical, and treatment-related predictors
Gepant users had 36% higher odds of achieving 24hPR compared to triptan users
No significant differences were observed in 2hPF outcomes between the two groups
Higher severity and frequency of migraines negatively impacted treatment effectiveness

Teichrow et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark